Ranbaxy Seeks Allies On Valsartan Market Exclusivity To Comply With FDA Manufacturing Requests
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy is making strategic moves to capitalize on its valsartan market exclusivity in the United States. Its latest plan may end a long impasse tied to repeated manufacturing concerns from FDA.